Ruxolitinib, inozivikanwawo se ruxolitinib muChina, ndeimwe ye "mishonga mitsva" yakave yakanyorwa zvakanyanya mumakiriniki mazano ekurapa zvirwere zvehematological mumakore achangopfuura, uye yakaratidza kubudirira kunovimbisa muzvirwere zvemyeloproliferative.
Mushonga wakanangwa Jakavi ruxolitinib unogona kunyatso kuvharidzira kuvhurwa kweiyo JAK-STAT chiteshi uye kuderedza chiratidzo chakasimudzirwa cheiyo chiteshi, nokudaro kubudirira.Inogona zvakare kushandiswa pakurapa kwemhando dzakasiyana dzezvirwere, uye kune JAK1 saiti abnormalities.
Ruxolitinibinonzi kinase inhibitor inoratidzirwa kurapwa kwevarwere vane myelofibrosis yepakati kana yakakwirira, kusanganisira primary myelofibrosis, post-geniculocytosis myelofibrosis, uye post-primary thrombocythemia myelofibrosis.
Chidzidzo chekiriniki chakafanana (n = 219) varwere vane pakati-panjodzi-2 kana yepamusoro-ngozi yepakutanga MF, varwere vane MF mushure mechokwadi erythroblastosis, kana varwere vane MF mushure mekutanga thrombocytosis kumapoka maviri, mumwe achigamuchira oral ruxolitinib 15 kusvika 20 mgbid. (n=146) uye mumwe wacho achiwana mushonga wakanaka wekudzora (n=73).Mhedziso yekutanga uye yakakosha yechipiri yekudzidza yaive yezana yevarwere vane ≥35% kuderedzwa kwespleen volume (yakaongororwa nemagnetic resonance imaging kana computed tomography) pavhiki 48 uye 24, maererano.Zvigumisiro zvakaratidza kuti chikamu chevarwere vane zvinopfuura 35% kuderedza spleen volume kubva pakutanga kwevhiki 24 yaiva 31.9% muboka rekurapa kana ichienzaniswa ne0% muboka rinodzora (P <0.0001);uye chikamu chevarwere vane zvinopfuura 35% kuderedza spleen volume kubva pakutanga kwevhiki 48 yaiva 28.5% muboka rekurapa kana ichienzaniswa ne0% muboka rinodzora (P <0.0001).Mukuwedzera, ruxolitinib yakaderedzawo zviratidzo zvakazara uye yakanyatsovandudza hupenyu hwevarwere.Zvichienderana nemhedzisiro yezviyedzo zviviri izvi zvekiriniki,ruxolitinibwakava mushonga wekutanga kubvumidzwa neUS FDA kurapwa kwevarwere vane MF.